Photopheresis Products Market To Reach US$ 423.2 Mn with CAGR 5.3% from 2019 to 2027

Transparency Market Research (TMR) has published a new report titled, Photopheresis Products Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global photopheresis products market was valued at US$ 262.4 Mn in 2018 and is projected to expand at a CAGR of above 5.3% from 2019 to 2027.

Overview
Photopheresis products are mainly used to treat cutaneous T-cell lymphoma conditions. In the photopheresis treatment procedure white blood cells are collected from the blood and they are mixed with photosensitizer and treated with UV light. New therapeutic indications options are boosting the growth of this market.
Furthermore, photopheresis therapy is majorly used in treating the patients who are not responding to steroids therapy in transplant rejection conditions. Photopheresis therapy is safer therapy when compared with steroids due to lack of side effects.
North America dominated the global photopheresis therapy market in 2018 and the trend is anticipated to continue during the forecast period, As Governments provide reimbursement for various disease indications such as GVHD, CTL, and lung transplantations that are treated by ECP therapy.

Get Exclusive PDF Sample Copy Of This Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14771

Corporate entities boosting the research activities on ECP therapy to Drive Photopheresis Products Market
Corporates are actively encouraging research on photopheresis treatment by providing monetary support to researchers.
In 2014, Freseinus Kabi conducted an award contest on advanced research in therapeutic apheresis and cell therapy. The company has granted US$ 100,000 to the research team led by John Koreth, Dana Farber Cancer Institute, for his work on treating chronic GvHD condition by using photopheresis and low-dose interleukin-2 (IL-2).

Closed System Segment to Capture Largest Market Share
Based on product, closed system devices has the highest revenue as compared to open systems and is expected to be dominate over the forecast period in 2019, as closed photopheresis system is the only FDA approved system to treat CTL conditions.

Graft versus host disease to dominate Market in Term of Therapeutic Application
Based on therapeutic area, the market has been segmented into cutaneous T-cell lymphoma, graft versus host disease, transplant rejections and autoimmune diseases. Graft versus host disease is expected to dominate the market over the forecast period due to increase in allogeneic stem cell transplantations worldwide. In addition to that, increase in usage of photopheresis therapy in organ transplantations are boosting the growth of this market over the forecast period

Buy Now@ https://www.transparencymarketresearch.com/checkout.php?rep_id=14771

Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.